We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagCA

888-969-2592

RY 167.35 0.5467% TD 87.16 0.6699% SHOP 114.42 1.4722% CNR 155.62 0.4259% ENB 55.85 0.6306% CP 109.89 -0.1091% BMO 123.0 0.0651% TRI 228.4 -0.3751% CNQ 49.83 0.4435% BN 72.45 1.2296% ATD 73.62 -1.0484% CSU 4323.3101 0.1958% BNS 71.22 -0.3916% CM 82.35 0.3779% SU 53.7 0.2053% TRP 61.7 1.2305% NGT 71.55 -0.6526% WCN 248.14 1.0877% MFC 40.83 0.2701% BCE 45.71 -0.1311%

Thiogenesis Therapeutics Corp.

Healthcare CA TTI

0.67CAD
-(-%)

Last update at 2024-10-08T17:37:00Z

Day Range

0.670.67
LowHigh

52 Week Range

0.490.90
LowHigh

Fundamentals

  • Previous Close 0.67
  • Market Cap39.93M
  • Volume500
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31
Income before tax -0.22446M -0.09268M -0.07334M
Minority interest - - -
Net income -0.22446M -0.09268M -0.07334M
Selling general administrative 0.22M 0.09M 0.06M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation - - -
Ebit - - -
Ebitda -0.22443M -0.09265M -0.07334M
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -0.22468M -0.09265M -0.07342M
Other operating expenses - - -
Interest expense 0.00003M 0.00003M 0.00000M
Tax provision - - -
Interest income 0.00025M 0.00000M 0.00008M
Net interest income 0.00022M -0.00003M 0.00008M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 0.22M 0.09M 0.07M
Cost of revenue - - -
Total other income expense net - - -
Discontinued operations - - -
Net income from continuing ops -0.22446M -0.09268M -0.07334M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31
Total assets 3.43M 0.15M 0.29M
Intangible assets - - -
Earning assets - - -
Other current assets - - -
Total liab 3.49M 0.06M 0.01M
Total stockholder equity -0.06107M 0.08M 0.28M
Deferred long term liab - - -
Other current liab - - -
Common stock - - -
Capital stock 0.30M 0.27M 0.00131M
Retained earnings -0.45342M -0.22897M -0.32709M
Other liab - - -
Good will - - -
Other assets - - -
Cash - 0.02M 0.18M
Cash and equivalents - - -
Total current liabilities 3.49M 0.06M 0.01M
Current deferred revenue - - -
Net debt - 0.30M -
Short term debt - - -
Short long term debt - 0.32M -
Short long term debt total - - -
Other stockholder equity - - -
Property plant equipment - - -
Total current assets 3.43M 0.15M 0.29M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables - 0.00135M 0.00229M
Long term debt - - -
Inventory - - -
Accounts payable - 0.03M 0.01M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 0.00000M 0.00000M 0.00000M
Capital lease obligations - - -
Long term debt total - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31
Investments - - -
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities 3.33M 0.00011M 0.35M
Change to operating activities - - -
Net income -0.22446M -0.09268M -0.07334M
Change in cash 3.26M -0.03577M 0.15M
Begin period cash flow 0.15M 0.18M 0.03M
End period cash flow 3.41M 0.15M 0.18M
Total cash from operating activities -0.06708M -0.03588M -0.19958M
Issuance of capital stock - 0.00000M 0.35M
Depreciation - - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - 0.00089M -0.00229M
Sale purchase of stock - - -
Other cashflows from financing activities - - -
Change to netincome - - -
Capital expenditures 0.00000M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.16M 0.06M -0.12624M
Stock based compensation - 0.03M 0.00000M
Other non cash items - 0.00351M -
Free cash flow -0.06708M -0.03588M -0.19958M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.67 - - - 11.86 -163.0787
NGEN
NervGen Pharma Corp		 -0.02 0.83% 2.39 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc		 -0.1 5.29% 1.79 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc		 - -% 0.09 - - 170.46 - 189.94 -48.7372
SBM
Sirona Biochem Corp		 - -% 0.08 - - 343.74 41.64 359.74 -13.882

Reports Covered

Stock Research & News

View All

Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet medical needs. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. The company is headquartered in Toronto, Canada.

Thiogenesis Therapeutics Corp.

4 King Street West, Toronto, ON, Canada, M5H 1B6

Key Executives

Name Title Year Born
Dr. Patrice P. Rioux M.D., Ph.D. CEO & Director 1951
Ms. Mary Jo Bagger Consultant for Clinical Operations NA
Mr. Brook G. Riggins C.F.A. CFO, Sec. & Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.